Diabetes Research
To learn more about diabetes and ongoing clinical trials in this area, visit our Diabetes Research page.
The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it.
Participants with body mass index (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m²)
Must be males or females not of childbearing potential
Part B and C - Participants with type 1 diabetes mellitus (T1DM) for at least 2 years treated with insulin
Participants must not have had heart disease or other heart conditions like heart attack, heart failure or stroke
Part B and C -
Have had more than 1 emergency treatment or hospitalization for very low blood sugar or very high blood sugar level in the past 6 months
Have been treated with Glucagon-like Peptide-1 Receptor Agonists (GLP1-RA), Dipeptidyl Peptidase 4 (DPP4) inhibitor, Glucose-dependent Insulinotropic Polypeptide (GIP) agonists, Metformin, or Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors within the previous 3 months
Participants who received systemic or inhaled glucocorticoid therapy
To learn more about diabetes and ongoing clinical trials in this area, visit our Diabetes Research page.
A clinical trial helps us learn if a new potential medicine or treatment works and how it works. Clinical trials are also called clinical research studies. To learn more about what to expect when taking part in a clinical trial, visit our Clinical Trial Information page.